Genprex, Inc. (GNPX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Genprex, Inc. (GNPX) Healthcare & Pipeline Overview

Genprex, Inc. is a clinical-stage biotechnology company specializing in gene therapies for cancer and diabetes, with a primary focus on REQORSA (GPX-001) for lung cancer treatment. The company operates in the competitive biotechnology sector, striving to advance its clinical pipeline and secure regulatory approvals.

What Is the Investment Thesis for GNPX?

Genprex, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product candidate, REQORSA, targeting NSCLC and SCLC, represents a significant potential value driver, contingent on successful clinical trial outcomes and regulatory approvals. Positive Phase II data could serve as a major catalyst, potentially leading to partnerships or acquisition interest. The development of GPX-002 for diabetes offers further upside potential, although it is in the early preclinical stage. Key risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund operations. With a small market cap and limited revenue, Genprex's stock price is highly sensitive to news flow and investor sentiment. The company's success hinges on its ability to execute its clinical development plan and secure necessary funding.

Based on FMP financials and quantitative analysis

GNPX Key Highlights

Genprex's lead product candidate, REQORSA (GPX-001), is in clinical development for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

• The company is also developing GPX-002, a preclinical stage gene therapy for diabetes, indicating a diversified pipeline approach.
• Genprex is a clinical-stage company, meaning it has not yet generated revenue from product sales and relies on funding to advance its pipeline.
• The company has a small team of 15 employees, reflecting its current stage of development and operational scale.
• Genprex's market capitalization is $0.00B, indicating its status as a micro-cap company with potentially high volatility.

Who Are GNPX's Competitors?

GNPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GNPX's Key Strengths?

Novel gene therapy platform.

• Lead product candidate (REQORSA) in clinical development.
• Focus on unmet medical needs in cancer and diabetes.

What Are GNPX's Weaknesses?

Limited financial resources.

• Small team and infrastructure.
• Reliance on clinical trial success and regulatory approvals.

What Could Drive GNPX Stock Higher?

Announcement of Phase II clinical trial results for REQORSA in NSCLC.

• Initiation of clinical trials for REQORSA in SCLC.
• Progress in preclinical development of GPX-002 for diabetes.

What Are the Key Risks for GNPX?

Financial-distress signal — its Altman Z-Score of -16.28 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for REQORSA.
• Regulatory delays or rejection of REQORSA.
• Need for additional capital to fund operations.
• Competition from other companies developing cancer and diabetes therapies.

What Are the Growth Opportunities for GNPX?

• Growth opportunity 1: Successful clinical trials for REQORSA in NSCLC and SCLC represent a significant growth opportunity. Positive Phase II data could lead to accelerated development and potential FDA approval. The market for lung cancer therapies is substantial, with a global market size estimated at billions of dollars annually. Achieving regulatory approval and commercializing REQORSA could generate substantial revenue for Genprex and establish it as a key player in the lung cancer treatment market. The timeline for this growth opportunity is dependent on the progress of ongoing and future clinical trials.
• Growth opportunity 2: The development of GPX-002 for diabetes offers a longer-term growth opportunity for Genprex. Diabetes is a widespread and growing global health problem, creating a large market for effective treatments. While GPX-002 is currently in the preclinical stage, successful preclinical studies and subsequent clinical trials could lead to a novel gene therapy for diabetes. This would diversify Genprex's product pipeline and potentially generate significant revenue in the future. The timeline for this growth opportunity extends several years into the future.
• Growth opportunity 3: Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate Genprex's growth. Partnering with a larger company could provide Genprex with access to additional funding, expertise, and resources to advance its clinical programs. This could also facilitate the commercialization of REQORSA and GPX-002, if approved. The timing and nature of potential partnerships are uncertain, but they represent a significant growth opportunity for Genprex.
• Growth opportunity 4: Expansion of the REQORSA platform to treat other types of cancer represents a potential growth opportunity. If REQORSA proves to be effective in treating NSCLC and SCLC, Genprex could explore its potential in other cancer indications. This would broaden the market opportunity for REQORSA and potentially generate additional revenue streams. The timeline for this growth opportunity is dependent on the success of REQORSA in its initial indications.
• Growth opportunity 5: Securing orphan drug designation for REQORSA in specific subsets of lung cancer patients could provide Genprex with regulatory and commercial advantages. Orphan drug designation provides incentives such as market exclusivity and tax credits, which could enhance the value of REQORSA and make it more attractive to potential partners. The timeline for securing orphan drug designation is dependent on the specific regulatory requirements and the availability of clinical data.

What Are GNPX's Competitive Advantages?

• Proprietary gene therapy technology platform.
• Patent protection for REQORSA and GPX-002.
• Clinical data supporting the safety and efficacy of REQORSA.

What Does GNPX Do?

Genprex, Inc., founded in 2009 and headquartered in Austin, Texas, is a clinical-stage gene therapy company dedicated to developing innovative treatments for cancer and diabetes. The company's lead product candidate, REQORSA (GPX-001), is designed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). REQORSA utilizes a novel mechanism of action to target cancer cells and improve patient outcomes. In addition to REQORSA, Genprex is also developing GPX-002, a preclinical-stage gene therapy for diabetes. This therapy aims to address the underlying causes of diabetes by delivering genes that can help regulate blood sugar levels. Genprex's strategy involves advancing its product candidates through clinical trials, seeking regulatory approvals, and ultimately commercializing its therapies to improve the lives of patients with cancer and diabetes. The company operates within the highly competitive biotechnology industry, focusing on innovative gene therapy approaches to address unmet medical needs.

What Products and Services Does GNPX Offer?

• Develops gene therapies for cancer and diabetes.
• Focuses on REQORSA (GPX-001) for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Develops GPX-002, a preclinical-stage gene therapy for diabetes.
• Seeks regulatory approvals from agencies like the FDA to commercialize its therapies.
• Engages in research and development to discover and develop new gene therapies.

How Does GNPX Make Money?

• Develops and patents gene therapy technologies.
• Outlicenses or partners with larger pharmaceutical companies for commercialization.
• Raises capital through equity offerings and grants to fund research and development.

What Industry Does GNPX Operate In?

Genprex operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Gene therapy is an emerging field within biotechnology, offering the potential to treat diseases at their genetic roots. Genprex's focus on REQORSA for lung cancer positions it within a competitive landscape that includes established pharmaceutical companies and other biotechnology firms developing novel cancer treatments. Success in this industry requires strong scientific expertise, effective clinical trial execution, and the ability to navigate the complex regulatory approval process.

Who Are GNPX's Key Customers?

• Patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• Patients with diabetes.
• Pharmaceutical companies interested in licensing or acquiring gene therapy technologies.

Wall Street analysts project Genprex, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1265.00.

GNPX Valuation & Market Position

With a $1.99M market cap, Genprex, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GNPX's quantitative score of 29/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -82.4%, showing how much profit it generates from its asset base. A current ratio of 5.61 indicates the company holds enough short-term assets to cover its near-term obligations.

Genprex, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.28 places it in the distress zone, a signal of elevated financial risk.

Genprex, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 21.7% below estimates on average.

Company Profile

Genprex, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Ryan Confer. GNPX has traded publicly since 2018.

GNPX Financials

GNPX Latest News

GNPX Analyst Consensus

GNPX MoonshotScore

Genprex, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources